1
|
Al-Melh MA, Farghal M, Abdelall N. Abstracts of the RCPsych International Congress 2022, 20-23 June. BJPsych Open 2022; 8:S1-S182. [PMID: 35723212 PMCID: PMC9372568 DOI: 10.1192/bjo8_s1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
AIMS Multiple sclerosis (MS) is an autoimmune disease characterized by focal demyelinating lesions that can affect any part of the central nervous system. The highlight of the disease is the wide range of neurological deficits; however, psychiatric manifestations are not uncommon. MS is associated with psychiatric comorbidities, such as depression and anxiety disorders. This is due to either its disease process or its therapies that have been well documented in the literature. However, the link between psychosis as a prodrome and MS remains understudied and relatively uncommon. METHODS We present a 40-year-old gentleman who developed isolated psychiatric manifestations for about 10 years in the form of progressive behavioral changes, social and occupational dysfunction, coupled with persecutory delusions. No personal or family history of mental illnesses. He was diagnosed and treated as a case of schizophrenia by a psychiatrist with multiple antipsychotics with a minimal improvement of his symptoms. Three months before our assessment the patient had a history of difficulty walking associated with urine and fecal incontinence. On examination, he had restricted affect and was easily agitated. Neurological examination revealed hypertonia and hyperreflexia in his left upper and lower limbs with normal power bilaterally. T2-weighted magnetic resonance imaging (MRI) brain showed multiple non-enhancing characteristic demyelinating lesions with typical shape and distribution. Further work-up was done to confirm the diagnosis of MS and exclude differentials, including a negative autoimmune screen, anti-aquaporin-4 (AQP4), and Myelin oligodendrocyte glycoprotein (MOG) antibodies. Visual evoked potentials documented bilateral severe disturbance in the visual pathway in both eyes, suggesting axonal loss. The patient is a candidate for a disease-modifying therapy for MS. Natalizumab or Ocrelizumab was selected based on his clinical criteria and will be started after proper preparation. RESULTS Psychiatric comorbidities in MS are associated with reduced compliance to disease-modifying therapies and lower quality of life. Studies reported that lesions in the periventricular area in the temporal region may be associated with psychosis, but not as an isolated presentation in patients with MS. CONCLUSION MS is one of the differentials of psychotic disorder due to a medical condition, and rarely may present with pure psychiatric manifestations preceding any obvious neurological deficits, leading to delay in the diagnosis. Despite being uncommon, a high index of suspicion should be kept in patients with atypical presentations associated with limited response to multiple antipsychotics. This highlights the importance of conducting a thorough physical examination and work-up to exclude an organic pathology, necessitating proper management.
Collapse
|
2
|
Khalil H, Aldaajani ZF, Aldughmi M, Al-Sharman A, Mohammad T, Mehanna R, El-Jaafary SI, Dahshan A, Ben Djebara M, Kamel WA, Amer HA, Farghal M, Abdulla F, Al-Talai N, Snineh MA, Farhat N, Jamali FA, Matar RK, Abdelraheem HS, Ghonimi NAM, Al-Melh MA, Elbhrawy S, Alotaibi MS, Elaidy SA, Almuammar SA, Al-Hashel JY, Gouider R, Samir H, Mhiri C, Skorvanek M, Lin J, Martinez-Martin P, Stebbins GT, Luo S, Goetz CG, Bajwa JA. Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Mov Disord 2022; 37:826-841. [PMID: 35218056 DOI: 10.1002/mds.28905] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Accepted: 11/06/2021] [Indexed: 11/07/2022] Open
Abstract
BACKGROUND The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has become the gold standard for evaluating different domains in Parkinson's disease (PD), and it is commonly used in clinical practice, research, and clinical trials. OBJECTIVES The objectives are to validate the Arabic-translated version of the MDS-UPDRS and to assess its factor structure compared with the English version. METHODS The study was carried out in three phases: first, the English version of the MDS-UPDRS was translated into Arabic and subsequently back-translated into English by independent translation team; second, cognitive pretesting of selected items was performed; third, the Arabic version was tested in over 400 native Arabic-speaking PD patients. The psychometric properties of the translated version were analyzed using confirmatory factor analysis (CFA) as well as exploratory factor analysis (EFA). RESULTS The factor structure of the Arabic version was consistent with that of the English version based on the high CFIs for all four parts of the MDS-UPDRS in the CFA (CFI ≥0.90), confirming its suitability for use in Arabic. CONCLUSIONS The Arabic version of the MDS-UPDRS has good construct validity in Arabic-speaking patients with PD and has been thereby designated as an official MDS-UPDRS version. The data collection methodology among Arabic-speaking countries across two continents of Asia and Africa provides a roadmap for validating additional MDS rating scale initiatives and is strong evidence that underserved regions can be energically mobilized to promote efforts that apply to better clinical care, education, and research for PD. © 2022 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Hanan Khalil
- Department of Physical Therapy and Rehabilitation Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.,Faculty of Applied Medical Sciences, Department of Rehabilitation Sciences, Jordan University of Science and Technology, Irbid, Jordan
| | | | - Mayis Aldughmi
- Department of Physiotherapy, School of Rehabilitation Sciences, University of Jordan, Amman, Jordan
| | - Alham Al-Sharman
- Faculty of Applied Medical Sciences, Department of Rehabilitation Sciences, Jordan University of Science and Technology, Irbid, Jordan
| | - Tareq Mohammad
- National Neuroscience Nursing Administration, Executive Administration of Nursing Affairs, Riyadh, Saudi Arabia
| | - Raja Mehanna
- University of Texas Health Science Center at Houston - McGovern Medical School, Houston, Texas, USA
| | - Shaimaa I El-Jaafary
- Neurology Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
| | - Ahmed Dahshan
- Neurology Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
| | - Mouna Ben Djebara
- Department of Neurology, Clinical Investigation Center - Razi University Hospital, Faculté de Médecine de Tunis, Université Tunis El Manar, Tunis, Tunisia
| | - Walaa A Kamel
- Neurology department, Beni-Suef University, Egypt.,Neurology Department- Ibn Sina Hospital, Kuwait City, Kuwait
| | - Hanan A Amer
- Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
| | | | - Fatema Abdulla
- Clinical Neuroscience Department, Salmaniya Medical Complex, Manama, Bahrain
| | | | | | - Nouha Farhat
- Department of Neurology, Clinical Investigation Center - Habib Bourguiba Hospital University Center, Sfax, Tunisia
| | | | - Rawan K Matar
- Neurology Division, Al-Adan Hospital, Kuwait City, Kuwait
| | - Heba S Abdelraheem
- Department of Neurology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | | | | | - Sonia Elbhrawy
- Department of Neurology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | | | | | | | - Jasem Y Al-Hashel
- Neuroscience Centre, King Fahd Specialist Hospital, Dammam, Saudi Arabia
| | - Riadh Gouider
- Department of Neurology, Clinical Investigation Center - Razi Hospital, Faculté de Médecine de Tunis, Tunis El Manar University, Tunis, Tunisia
| | - Hatem Samir
- Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
| | - Chokri Mhiri
- Cell Therapy Center, University of Jordan, Amman, Jordan
| | - Matej Skorvanek
- Department of Neurology, P. J. Safarik University, Kosice, Kosice, Slovak Republic.,Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic
| | - Jeffrey Lin
- Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Pablo Martinez-Martin
- Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain
| | - Glenn T Stebbins
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA
| | - Sheng Luo
- Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA
| | - Christopher G Goetz
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA
| | - Jawad A Bajwa
- Department of Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia
| |
Collapse
|
3
|
Khalil H, Chahine LM, Siddiqui J, Salari M, El-Jaafary S, Aldaajani Z, Abu Al-Melh M, Mohammad TM, Abu Snineh M, Syed NA, Bhatt M, Habib MA, Habahbeh M, Tabbal SD, Jeon B, Bajwa JA. Parkinson's Disease in the Middle East, North Africa, and South Asia: Consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East. J Parkinsons Dis 2020; 10:729-741. [PMID: 32176653 PMCID: PMC8203232 DOI: 10.3233/jpd-191751] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Accepted: 02/09/2020] [Indexed: 12/31/2022]
Abstract
BACKGROUND Understanding the regional needs and available healthcare resources to treat Parkinson's disease (PD) is essential to plan appropriate future priorities. The International Parkinson and Movement Disorder Society (MDS) Task Force for the Middle East was established to raise awareness and promote education across the region on PD and other movement disorders. Broadly, the task force encompasses the countries of the Middle East but has included North Africa and South Asia as well (MENASA). OBJECTIVE To create a list of needs and priorities in the advancement of PD in MENASA countries based on consensuses generated by the MDS task force for the Middle East. METHODS A Strengths Weaknesses-Opportunities-Threats (SWOT) analysis was conducted by the task force members to generate consensus about PD care this region. RESULTS Eight overarching principles emerged for the consensus statement on current needs: more movement disorders specialists, multidisciplinary care, accurate epidemiologic data, educational programs, availability of drugs, and availability of more advanced therapy, enhanced health care resources and infrastructure, and greater levels of awareness within the general population and among health care professionals. CONCLUSION This pilot study sheds light on unmet needs for providing care to people with PD in the MENASA region. These data offer directions on priorities to increase awareness of PD, to develop better infrastructure for research and management of PD, to foster healthcare policy discussions for PD and to provide educational opportunities within these countries.
Collapse
Affiliation(s)
- Hanan Khalil
- Department of Rehabilitation Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan
| | - Lana M. Chahine
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Junaid Siddiqui
- Department of Neurology, University of Missouri, Columbia, MO, USA
| | - Mehri Salari
- Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - Zakiyah Aldaajani
- Neurology Unit, King Fahad Medical Military Complex, Dahran, Saudi Arabia
| | | | | | | | | | - Mohit Bhatt
- Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai, India
| | - Mohammad Ahsan Habib
- Department of Neurology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
| | - Majed Habahbeh
- Department of Medicine, Neurology Section, King Hussein Medical Centre, Amman, Jordan
| | - Samer D. Tabbal
- Department of Neurology, Parkinson & Movement Disorders Program, American University of Beirut Medical Centre, Beirut, Lebanon
| | - Beomseok Jeon
- Department of Neurology, Movement Disorders Center, Seoul National University, Seoul, South Korea
| | - Jawad A. Bajwa
- Department of Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia
| |
Collapse
|